TRIMming P53's Anticancer Activity

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2016 Feb 23

PMID 26898759

Citations 28

Authors

S ElAbd

G Meroni

C Blattner

Affiliations

Soon will be listed here.

Abstract

Several TRIM proteins control abundance and activity of p53. Along this route, TRIM proteins have a serious impact on carcinogenesis and prognosis for cancer patients. In the past years, a significant increase has been made in our understanding of how the TRIM protein family controls p53 activity.

Citing Articles

Tripartite motif-containing protein 26 promotes colorectal cancer growth by inactivating p53.

Tan Z, Ko H, Naji P, Zhu R, Wang J, Huang S Cell Death Differ. 2025; .

PMID: 39994352 DOI: 10.1038/s41418-025-01463-1.

Exploring the Mechanisms, Biomarkers, and Therapeutic Targets of TRIM Family in Gastrointestinal Cancer.

Weng C, Jin R, Jin X, Yang Z, He C, Zhang Q Drug Des Devel Ther. 2024; 18:5615-5639.

PMID: 39654601 PMC: 11626976. DOI: 10.2147/DDDT.S482340.

TRIM59-mediated ferroptosis enhances neuroblastoma development and chemosensitivity through p53 ubiquitination and degradation.

Liu Y, Jiang N, Chen W, Zhang W, Shen X, Jia B Heliyon. 2024; 10(4):e26014.

PMID: 38434050 PMC: 10906161. DOI: 10.1016/j.heliyon.2024.e26014.

Comprehensive Analysis of the Prognostic Significance of the TRIM Family in the Context of TP53 Mutations in Cancers.

Vu T, Fowler A, McCarty N Cancers (Basel). 2023; 15(15).

PMID: 37568609 PMC: 10417774. DOI: 10.3390/cancers15153792.

TRIM8: a double-edged sword in glioblastoma with the power to heal or hurt.

Hosseinalizadeh H, Mohamadzadeh O, Kahrizi M, Razaghi Bahabadi Z, Klionsky D, Mirzei H Cell Mol Biol Lett. 2023; 28(1):6.

PMID: 36690946 PMC: 9869596. DOI: 10.1186/s11658-023-00418-z.

References

Kano S, Miyajima N, Fukuda S, Hatakeyama S . Tripartite motif protein 32 facilitates cell growth and migration via degradation of Abl-interactor 2. Cancer Res. 2008; 68(14):5572-80. DOI: 10.1158/0008-5472.CAN-07-6231. View

Ho J, Kong J, Choong L, Loh M, Toy W, Chong P . Novel breast cancer metastasis-associated proteins. J Proteome Res. 2008; 8(2):583-94. DOI: 10.1021/pr8007368. View

Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci P, Dejean A . Deconstructing PML-induced premature senescence. EMBO J. 2002; 21(13):3358-69. PMC: 126090. DOI: 10.1093/emboj/cdf341. View

Caratozzolo M, Valletti A, Gigante M, Aiello I, Mastropasqua F, Marzano F . TRIM8 anti-proliferative action against chemo-resistant renal cell carcinoma. Oncotarget. 2014; 5(17):7446-57. PMC: 4202135. DOI: 10.18632/oncotarget.2081. View

Wang L, Heidt D, Lee C, Yang H, Logsdon C, Zhang L . Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell. 2009; 15(3):207-19. PMC: 2673547. DOI: 10.1016/j.ccr.2009.01.018. View

Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M . Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature. 2002; 417(6891):871-5. DOI: 10.1038/nature00826. View

Short K, Cox T . Subclassification of the RBCC/TRIM superfamily reveals a novel motif necessary for microtubule binding. J Biol Chem. 2006; 281(13):8970-80. DOI: 10.1074/jbc.M512755200. View

Yang S, Kuo C, Bisi J, Kim M . PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol. 2002; 4(11):865-70. DOI: 10.1038/ncb869. View

Rokudai S, Laptenko O, Arnal S, Taya Y, Kitabayashi I, Prives C . MOZ increases p53 acetylation and premature senescence through its complex formation with PML. Proc Natl Acad Sci U S A. 2013; 110(10):3895-900. PMC: 3593914. DOI: 10.1073/pnas.1300490110. View

10.

Wittmann S, Wunder C, Zirn B, Furtwangler R, Wegert J, Graf N . New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors. Genes Chromosomes Cancer. 2008; 47(5):386-95. DOI: 10.1002/gcc.20544. View

11.

Li Q, He Y, Wei L, Wu X, Wu D, Lin S . AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation. Oncogene. 2010; 30(10):1194-204. DOI: 10.1038/onc.2010.499. View

12.

Louria-Hayon I, Grossman T, Sionov R, Alsheich O, Pandolfi P, Haupt Y . The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem. 2003; 278(35):33134-41. DOI: 10.1074/jbc.M301264200. View

13.

Tang Z, Dong Q, Cui Q, Papavassiliou P, Wang E, Wang E . Ataxia-telangiectasia group D complementing gene (ATDC) promotes lung cancer cell proliferation by activating NF-κB pathway. PLoS One. 2013; 8(6):e63676. PMC: 3680444. DOI: 10.1371/journal.pone.0063676. View

14.

Meroni G, Diez-Roux G . TRIM/RBCC, a novel class of 'single protein RING finger' E3 ubiquitin ligases. Bioessays. 2005; 27(11):1147-57. DOI: 10.1002/bies.20304. View

15.

Boehme K, Blattner C . Regulation of p53--insights into a complex process. Crit Rev Biochem Mol Biol. 2009; 44(6):367-92. DOI: 10.3109/10409230903401507. View

16.

Haupt S, Di Agostino S, Mizrahi I, Alsheich-Bartok O, Voorhoeve M, Damalas A . Promyelocytic leukemia protein is required for gain of function by mutant p53. Cancer Res. 2009; 69(11):4818-26. DOI: 10.1158/0008-5472.CAN-08-4010. View

17.

Herquel B, Ouararhni K, Khetchoumian K, Ignat M, Teletin M, Mark M . Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2011; 108(20):8212-7. PMC: 3100982. DOI: 10.1073/pnas.1101544108. View

18.

Mu Z, Chin K, Liu J, Lozano G, Chang K . PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol. 1994; 14(10):6858-67. PMC: 359216. DOI: 10.1128/mcb.14.10.6858-6867.1994. View

19.

Vaseva A, Marchenko N, Moll U . The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells. Cell Cycle. 2009; 8(11):1711-9. PMC: 2823264. DOI: 10.4161/cc.8.11.8596. View

20.

Yang B, OHerrin S, Wu J, Reagan-Shaw S, Ma Y, Bhat K . MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res. 2007; 67(20):9954-62. DOI: 10.1158/0008-5472.CAN-07-1478. View